TAPI-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

TAPI-1  纯度: ≥99.0%

TAPI-1 是一种 TACE (ADAM17) 抑制剂，可阻止多种细胞表面蛋白脱落。TAPI-1 也是金属蛋白酶 (MMP) 抑制剂。

TAPI-1

TAPI-1 Chemical Structure

CAS No. : 163847-77-6

规格 价格 是否有货 数量
1 mg ￥1804 In-stock
5 mg ￥6600 In-stock
10 mg ￥11800 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

生物活性

TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins[1]. TAPI-1 is also a metalloproteinase (MMP) inhibitor[2].

IC50 & Target

TACE (ADAM17)[1], MMP[2]
体外研究
(In Vitro)

TAPI-1 (1 µM for 30 min) increases cell viability in LPS-treated HK-2 cells[1].
TAPI-1 attenuates oxidative stress and inflammatory cytokines[1]
LPS treatment significantly induces renal IL-6 and TNFα mRNA expression, while these changes is attenuated with TAPI-1 pretreatment in LPS-treated HK-2 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: LPS-treated HK-2 cells
Concentration: 1 µM
Incubation Time: 30 minutes (pre-treated)
Result: Increased cell viability.

分子量

499.60

Formula

C26H37N5O5
CAS 号

163847-77-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 31 mg/mL (62.05 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0016 mL 10.0080 mL 20.0160 mL
5 mM 0.4003 mL 2.0016 mL 4.0032 mL
10 mM 0.2002 mL 1.0008 mL 2.0016 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Bae EH, et al. Tumor necrosis factor α-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells. Korean J Physiol Pharmacol. 2018 Mar;22(2):135-143.

    [2]. Moss ML, et al. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017;2017:9673537.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务